Devyser Diagnostics Balance Sheet Health
Financial Health criteria checks 6/6
Devyser Diagnostics has a total shareholder equity of SEK381.0M and total debt of SEK200.0K, which brings its debt-to-equity ratio to 0.05%. Its total assets and total liabilities are SEK493.1M and SEK112.1M respectively. Devyser Diagnostics's EBIT is SEK34.8M making its interest coverage ratio -6. It has cash and short-term investments of SEK81.0M.
Key information
0.052%
Debt to equity ratio
SEK 200.00k
Debt
| Interest coverage ratio | -6x |
| Cash | SEK 81.00m |
| Equity | SEK 381.00m |
| Total liabilities | SEK 112.10m |
| Total assets | SEK 493.10m |
Recent financial health updates
We Think Devyser Diagnostics (STO:DVYSR) Can Easily Afford To Drive Business Growth
Just because a business does not make any money, does not mean that the stock will go down. For example, although...Companies Like Devyser Diagnostics (STO:DVYSR) Are In A Position To Invest In Growth
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...Devyser Diagnostics (STO:DVYSR) Is In A Strong Position To Grow Its Business
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...Recent updates
Financial Position Analysis
Short Term Liabilities: DVYSR's short term assets (SEK206.0M) exceed its short term liabilities (SEK70.6M).
Long Term Liabilities: DVYSR's short term assets (SEK206.0M) exceed its long term liabilities (SEK41.5M).
Debt to Equity History and Analysis
Debt Level: DVYSR has more cash than its total debt.
Reducing Debt: DVYSR's debt to equity ratio has reduced from 1.8% to 0.05% over the past 5 years.
Debt Coverage: DVYSR's debt is well covered by operating cash flow (12950%).
Interest Coverage: DVYSR earns more interest than it pays, so coverage of interest payments is not a concern.
Balance Sheet
Discover healthy companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/07/28 19:48 |
| End of Day Share Price | 2026/07/28 00:00 |
| Earnings | 2026/06/30 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Devyser Diagnostics AB (publ) is covered by 4 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Erik Hultgård | Carnegie Investment Bank AB |
| Erik Hultgård | DNB Carnegie |
| Ludvig Lundgren | Nordea Markets |